ZGNX News and Press, Zogenix Inc. From 10/07/19

Safety and efficacy data from a global, retrospective Phase 2 study (RETRO) support potential for deoxynucleoside substrate enhancement therapy (SET) to treat TK2 deficiency, an often-fatal mitochondrial DNA depletion disorder Highly significant impact on survival probability (p<0.00...

EMERYVILLE, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has resubmitted its New Drug Application (NDA) for FINTEPLA® (ZX008, fenfluramine) for the treatment of seizur...

Zogenix (NASDAQ: ZGNX ) has completed its acquisition of Modis Therapeutics, a privately-held biopharmaceutical company. More news on: Zogenix, Inc., Healthcare stocks news, Read more ...

EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it has successfully completed its acquisition of Modis Therapeutics, Inc., a privately-held biopharmaceutical company,...

Shares of rare-disease drugmaker Zogenix   (NASDAQ: ZGNX) fell 11.4% in August, according to data provided by S&P Global Market Intelligence . That was a much worse performance than the  S&P 500 , which was only off 1.8% for the month. This isn't the first wild monthly swin...

Monday was a good day on Wall Street, as investors were pleased to see the U.S. take more conciliatory positions on trade issues with major foreign powers. Fears of a global recession  are still present, but market participants acknowledge that if news out of Washington gets less confronta...

Shares of Zogenix (NASDAQ: ZGNX) closed Monday about 8.5% lower, a decline precipitated by the biotech's announcement that it plans to acquire privately held Modis Therapeutics for $250 million.  Investing in biotech stocks , especially clinical-stage biotechs, is fraught with risk fo...

Pipeline diversification makes sense, says analyst Danielle Brill, but investors here may be spooked by an acquisition so close to the FDA decision on Fintepla. The purchase also makes Zogenix (NASDAQ: ZGNX ) a far less likely target for a buyer, she adds. More news on: Zogenix, Inc., Heal...

Zogenix (NASDAQ: ZGNX ) has agreed to acquire privately held Oakland, CA-based Modis Therapeutics , a developer of therapies for rare inherited diseases. Lead candidate is MT1621 for the treatment of thymidine kinase 2 deficiency, an inherited mitochondrial DNA depletion disorder that is ...

Advances Zogenix’s strategy to provide transformative therapies to patients and families living with serious rare diseases Adds MT1621, a proprietary, late-stage investigational medicine targeting Thymidine Kinase 2 deficiency (TK2d) that has received FDA Breakthrough Thera...